Compare Dollar General Corp. (DG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Illumina, Inc. — how do they compare? Dollar General Corp. trades at $124.27 (market cap $26.95B), while Illumina, Inc. trades at $265 (market cap $40.43B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Dollar General Corp. pays a 1.93% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Illumina, Inc. for 83 Days on average.
| DG | ILMN | |
|---|---|---|
Market Cap | $26.95B | $40.43B |
Volume | 1,654,929 | 2,948,626 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $293.69 |
52-Week Low | $95.94 | $91.00 |
Typical Hold Time | 59 Days | 83 Days |
Enterprise Value | $41.13B | $41.79B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 0.82% on the day, with a neutral technical signal and bearish moving average trend. The stock shows strong valuation metrics with a P/E of 15.86 and P/S of 0.62, while recent earnings have consistently beaten estimates. Revenue growth is steady, reaching $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart.
The outlook is cautiously optimistic, supported by analyst consensus price target of $137.27 (10.5% upside) and a 55.77% buy rating. Key opportunities include margin recovery initiatives and digital growth, while risks involve competitive pressures and consumer spending volatility. The stock presents a value opportunity with upside potential if execution improves.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
